Iradimed Corporation has reported record-breaking financial results for the second quarter of 2025, with revenue reaching $20.4 million, marking a 14% increase compared to the same period in 2024. The company's GAAP diluted EPS also saw a significant uptick, reaching $0.45, marking an 18% increase year-over-year. Non-GAAP diluted EPS followed suit, reaching $0.49, a 17% increase compared to the same period in 2024.
The company's performance for the six months ended June 30, 2025, also showcased strong growth, with revenue reaching $39.9 million, a 12% increase compared to the same period in 2024. Net income for this period was reported at $10.5 million, marking a 16% increase year-over-year, with diluted EPS reaching $0.82, a 16% increase compared to the same period in 2024. Non-GAAP net income for the six months ended June 30, 2025, was $11.7 million, a 17% increase compared to the same period in 2024, with non-GAAP diluted EPS reaching $0.91, a 15% increase compared to the same period in 2024.
The breakdown of revenue for the three months ended June 30, 2025, shows significant growth across multiple segments, including MRI-compatible IV infusion pump systems, MRI-compatible patient vital signs monitoring systems, ferro magnetic detection systems, amortization of extended warranty agreements, disposables, and services and other. Domestic sales accounted for 89% of total revenue for this period, with a consistent gross profit margin of 78%.
Cash flow from operations also demonstrated a positive trend, with $7.7 million reported for the three months ended June 30, 2025, marking a 17% increase compared to the same period in 2024. For the six months ended June 30, 2025, cash flow from operations reached $12.0 million, a 14% increase compared to the same period in 2024.
Looking ahead, the company has raised its full-year 2025 revenue and earnings guidance, now expecting revenue in the range of $80.0 million to $82.5 million, GAAP diluted EPS of $1.60 to $1.70, and non-GAAP diluted EPS of $1.76 to $1.86, all higher than the previous guidance announcement.
In addition, the company announced a regular quarterly cash dividend of $0.17 per share of common stock, payable on August 28, 2025, to stockholders of record as of the close of business on August 18, 2025.
Iradimed Corporation's relentless focus on operational excellence, along with its sustained growth trajectory, underscores its strong performance and commitment to delivering long-term stockholder value.
The company's expansion plans, including the commercialization of its next-generation MRI-compatible IV infusion pump, set the stage for continued growth and market leadership in the medical devices sector. As a result of these announcements, the company's shares have moved 10.53% on the market, and are now trading at a price of $64.48. Check out the company's full 8-K submission here.
